BRAF

Chr 7AD

B-Raf proto-oncogene, serine/threonine kinase

Also known as: B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1

This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017]

Primary Disease Associations & Inheritance

Adenocarcinoma of lung, somaticMIM #211980
Cardiofaciocutaneous syndromeMIM #115150
AD
Colorectal cancer, somaticMIM #114500
LEOPARD syndrome 3MIM #613707
AD
Melanoma, malignant, somaticMIM #155600
Nonsmall cell lung cancer, somaticMIM #211980
Noonan syndrome 7MIM #613706
AD
UniProtFamilial non-Hodgkin lymphoma
1612
ClinVar variants
13
Pathogenic / LP
1.00
pLI score· haploinsufficient
12
Active trials
Clinical SummaryBRAF
Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
13 Pathogenic / Likely Pathogenic· 230 VUS of 1612 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.21LOEUF
pLI 1.000
Z-score 5.91
OE 0.10 (0.050.21)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
3.72Z-score
OE missense 0.49 (0.430.55)
203 obs / 416.7 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.10 (0.050.21)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.49 (0.430.55)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.02
01.21.6
LoF obs/exp: 5 / 50.2Missense obs/exp: 203 / 416.7Syn Z: -0.22

ClinVar Variant Classifications

1612 submitted variants in ClinVar

Classification Summary

Pathogenic8
Likely Pathogenic5
VUS230
Likely Benign212
Benign4
Conflicting5
8
Pathogenic
5
Likely Pathogenic
230
VUS
212
Likely Benign
4
Benign
5
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
2
6
0
8
Likely Pathogenic
0
5
0
0
5
VUS
13
177
32
8
230
Likely Benign
2
4
82
124
212
Benign
0
0
3
1
4
Conflicting
5
Total15188123133464

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

BRAF · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

BRAF-related Noonan syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Skin
G2P ↗

BRAF-related LEOPARD syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Skin
G2P ↗

BRAF-related cardiofaciocutaneous syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkin
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Adenocarcinoma of lung, somatic

MIM #211980

Molecular basis of disorder known

Cardiofaciocutaneous syndrome

MIM #115150

Molecular basis of disorder known

Autosomal dominant

Colorectal cancer, somatic

MIM #114500

Molecular basis of disorder known

LEOPARD syndrome 3

MIM #613707

Molecular basis of disorder known

Autosomal dominant

Melanoma, malignant, somatic

MIM #155600

Molecular basis of disorder known

Nonsmall cell lung cancer, somatic

MIM #211980

Molecular basis of disorder known

Noonan syndrome 7

MIM #613706

Molecular basis of disorder known

Autosomal dominant
Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Colorectal CancerChemotherapy Effect

Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

RECRUITING
NCT05797467Phase PHASE3Sixth Affiliated Hospital, Sun Yat-sen UniversityStarted 2023-04-01
FOLFOX chemotherapy regimensBevacizumab
Metastatic Colorectal Cancer

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

ACTIVE NOT RECRUITING
NCT05217446Phase PHASE2PfizerStarted 2022-07-11
EncorafenibCetuximabPembrolizumab
Hairy Cell LeukemiaRecurrent Hairy Cell LeukemiaRefractory Hairy Cell Leukemia

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

RECRUITING
NCT06965114Phase PHASE1, PHASE2National Cancer Institute (NCI)Started 2026-06-27
Biospecimen CollectionBone Marrow AspirationBone Marrow Biopsy
Non Small Cell Lung CancerSmall Cell Lung CarcinomaNUT Carcinoma

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

RECRUITING
NCT05265429Dana-Farber Cancer InstituteStarted 2023-01-01
Data and Specimen Collection
Recurrent Malignant GliomaGlioblastomaAnaplastic Astrocytoma

Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

ACTIVE NOT RECRUITING
NCT07448480Blokhin's Russian Cancer Research CenterStarted 2026-02-01
Bevacizumab-Containing RegimensNon-Bevacizumab RegimensBRAF ± MEK Targeted Therapy
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

ACTIVE NOT RECRUITING
NCT03155620Phase PHASE2National Cancer Institute (NCI)Started 2017-07-31
Biopsy ProcedureBiospecimen CollectionBone Marrow Aspiration and Biopsy
Lung Cancer

Survival Outcomes of Lung Cancer

RECRUITING
NCT03647098Hunan Province Tumor HospitalStarted 2018-08-01
Treatment
Melanoma

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

RECRUITING
NCT06599619John KirkwoodStarted 2025-02-20
Single agent, adjuvant anti-PD1 therapy
Solid TumorsHematologic CancersMetastatic Cancers

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

ACTIVE NOT RECRUITING
NCT02304809Phase PHASE2UNICANCERStarted 2014-10-13
Vemurafenib
Colorectal Cancer MetastaticBrain Metastases, AdultRas (KRAS or NRAS) Gene Mutation

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

RECRUITING
NCT06449989Blokhin's Russian Cancer Research CenterStarted 2024-04-01
Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI
Colorectal CarcinomaLiver Metastases

Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness

NOT YET RECRUITING
NCT05881746Phase NAFudan UniversityStarted 2023-07-01
anatomical liver resectionnonanatomical liver resection
Colo-rectal Cancer

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

ACTIVE NOT RECRUITING
NCT06011772Phase EARLY_PHASE1Roswell Park Cancer InstituteStarted 2023-12-18
Recombinant Human EGF-rP64K/Montanide ISA 51 VaccineLeucovorinOxaliplatin